MedWatch

Synact changes strategy in phase 1 with its arthritis hope

Danish biotech company Synact Pharma did not get the results the company expected with its main asset AP1189 in a phase 1 study. The company is now trying again with a different delivery method, which will delay the drug's development up to a year.

Synact Pharma's CFO Henrik Stage (left), CEO Jeppe Øvlesen (mid) and CSO Thomas Jonassen (right) | Foto: Synact Pharma

Tuesday, Danish Synact Pharma, which is listed in Sweden, had to disappoint its investors with an announcement that the company's arthritis hope AP1189 has run into problems in a phase 1 study and that development will be delayed up to a year.

Synact Pharma's share fell approximately 50 percent on the stock exchange Tuesday, however, it is still higher than it was a year ago.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Patienter må vente længere på ny medicin

Siden Medicinrådet blev etableret i 2017, er patienternes ventetid på ny medicin blevet tre gange længere, konkluderer en analyse fra Lif, der vil have Medicinrådet til at droppe unødvendige vurderingsmetoder. Medicinrådet arbejder på at nedbringe sagsbehandlingstiderne.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier